Inceptive vs Illumina
Side-by-side comparison of AI visibility scores, market position, and capabilities
Inceptive designs synthetic RNA molecules for therapeutic applications using deep learning and high-throughput experiments; targets mRNA medicines, RNA-based vaccines, and gene regulation; raised $100M Series A led by Andreessen Horowitz;
About
Inceptive is a Berlin and San Francisco-based biotechnology company founded in 2021 by Jakob Uszkoreit (former senior scientist at Google Brain and co-inventor of the Transformer architecture), Rhiju Das (Stanford RNA biophysicist), and other co-founders. The company is applying deep learning to the problem of RNA design — predicting and engineering synthetic RNA sequences that fold into specific structures and perform specific biological functions, such as encoding therapeutic proteins (mRNA medicines), silencing disease genes (siRNA, antisense), or regulating cellular behavior through aptamers and riboswitches.
World's dominant DNA sequencing platform with ~80% market share; ~$4.34B FY2025 revenue. Powers clinical genomics, oncology diagnostics, and population-scale sequencing.
About
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applications. The company's sequencing-by-synthesis (SBS) chemistry and NovaSeq, NextSeq, and MiSeq instrument platforms have become the standard infrastructure for genomic research, clinical oncology, reproductive health, and infectious disease diagnostics worldwide.\n\nIllumina's business model combines high-margin consumable sales (flow cells, reagent kits) with instrument placements, creating a razor-and-blades recurring revenue structure. Its clinical sequencing segment showed accelerating growth in 2025, with clinical consumables revenue up 20% year-over-year in Q4. The company is expanding into spatial transcriptomics and multi-omics with new instruments unveiled at AGBT 2025, broadening its addressable market.\n\nIllumina reported $4.34 billion in FY2025 revenue and guides to $4.5–$4.6 billion for FY2026, with non-GAAP operating margins of ~23%. Having divested Grail (its liquid biopsy subsidiary) following regulatory pressure, Illumina is refocused on its core sequencing franchise and positioned to benefit from continued clinical adoption of genomic medicine.
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.